C4 Therapeutics, Inc.·4

Feb 1, 4:10 PM ET

White Lauren 4

4 · C4 Therapeutics, Inc. · Filed Feb 1, 2023

Insider Transaction Report

Form 4
Period: 2023-01-30
White Lauren
Chief Financial Officer
Transactions
  • Exercise/Conversion

    Common Stock

    2023-01-30+3,7506,398 total
  • Exercise/Conversion

    Performance Restricted Stock Units

    2023-01-303,75018,750 total
    Exp: 2025-02-28Common Stock (3,750 underlying)
  • Tax Payment

    Common Stock

    2023-01-30$7.78/sh1,301$10,1225,097 total
Footnotes (2)
  • [F1]Each performance restricted stock unit ("PRSU") represents the contingent right to receive one share of the Issuer's Common Stock upon vesting and settlement. 4,500 PRSUs shall vest upon satisfaction of three escalating share price vesting milestones, and the remaining PRSUs vest upon satisfaction of certain discovery and clinical milestones.
  • [F2]Represents shares withheld by the Issuer to satisfy tax withholding obligations in connection with the vesting and settlement of PRSUs and does not represent a sale by the Reporting Person.

Documents

1 file
  • 4
    wf-form4_167528583720918.xmlPrimary

    FORM 4